Renal protection by antihypertensive drugs: Insights from microalbuminuria studies

Journal of Hypertension

Volumn 16, Issue 12 SUPPL., 1998, Pages 2091-2100

  Redon, Josep ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Angiotensin II receptor antagonists; Angiotensin converting enzyme inhibitor; Antihypertensive treatment; Calcium channel blockers; Glomerular filtration rate; Hypertension; Microalbuminuria; Non diabetic renal disease; Proteinuria; Renal failure; blockers

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DIAGNOSTIC VALUE; DISEASE SEVERITY; EARLY DIAGNOSIS; ESSENTIAL HYPERTENSION; GLOMERULUS; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY; KIDNEY DISEASE; MICROALBUMINURIA; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; VASCULAR DISEASE;

EID: 0032407950     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816121-00035     Document Type: Conference Paper

References (79)

1. Mountokalakis TD: The renal consequences of arterial hypertension. Kidney Int 1997; 51:1639-1653.
2. Whelton PK, Klag MJ: Hypertension as a risk factor for renal disease: review of clinical and epidemiological evidence. Hypertension 1989; 13 (suppl 1): 119-117.
3. Schmieder RE: Nephroprotection by antihypertensive agents. J Cardiovasc Pharmacol 1994; 24 (suppl 2):S55-S64.
4. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford ChE, et al.: Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13-18.
5. Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL: Blood pressure and renal function: therapeutic implications. J Hypertens 1996; 14:1259-1263.
6. Perneger TV, Klag MJ, Feldmann HI, Whelton PK: Projections of hypertension-related renal disease in middle-age residents of the United States. JAMA 1993; 1272-1277.
7. Ritz E, Nowicki M, Fliser D, Hörner D, Klim HP: Proteinuria and hypertension. Kidney Int 1994; 46 (suppl 47):S76-S80.
8. United States Renal Data System: USRDS 1998 Annual Data Report. Bethesda: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease; 1998.
9. Ruilope LM, Alcazar JM, Rodicio JL: Renal consequences of arterial hypertension. J Hypertens 1990; 10 (suppl 7):S85-S90.
10. Weisstuch JM, Dworkin LD: Does essential hypertension cause end-stage renal disease? Kidney Int 1992; 41 (suppl 36):S33-S37.
11. Rodicio JL, Ruilope LM: Assessing renal effects and renal protection. J Hypertens 1995; 13 (suppl 4):S19-S25.
12. Epstein M, Parving HH, Ruilope LM: Surrogate endpoints and renal protection: focus on microalbuminuria. Blood Press 1997; 12 (suppl 2): 52-57.
13. Raine AE: Hyperension and the kidney. Br Med Bull 1994; 50: 322-341.
14. Jhonson R, Schreiner GF: Hypothesis: the role of acquired tubulointertitial disease in the pathogenesis of salt-dependent hypertension. Kidney Int 1997; 52:1169-1179.
15. Koomans HA, Joles JA, Rabelink TJ: Hypertension and the kidney: culprit and victim. Nephrol Dial Transplant 1996; 11:1961-1966.
16. Samuelsson O: Hypertension in middle-age men: management, morbidity and prognostic factors during long term hypertensive care. Acta Med Scand 1985; 702 (suppl):1-79.
17. Mattei P, Arzilli F, Giovannetti R, Penno G, Arrighi P, Taddei S, Salvetti A: Microalbuminuria and renal haemodynamics in essential hypertension. Eur J Clin Invest 1997; 27:755-760.
18. Erley CM, Holzer M, Kramer BK, Risler T: Renal hemodynamics and organ damage in young hypertensive patients with different plasma renin activities after ACE inhibition. Nephrol Dial Transplant 1992; 7:216-220.
19. Rostand SG, Brown G, Kirk K, Rutsky EA, Dustan HP: Renal insufficiency in treated essentil hypertension. N Engl J Med 1989; 320:684-686.
20. Agrawal B, Berger A, Wolf K, Luft FC: Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14:223-228.
21. Ruilope LM, Campo C, Rodriguez-Artalejo F, Lahera V, Garcia-Robles R, Rodicio JL: Blood pressure and renal function: therapeutic implications. J Hypertens 1996; 14:1259-1263.
22. Bianchi S, Bigazzi R, Baldari G, Campese VM: Is microalbuminuria a predictor of cardiovascular and renal events in essential hypertension (EH)? [abstract]. J Am Soc Nephrol 1997; 8:313.
23. Halimi JM, Mimram A: Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995; 13:1801-1802.
24. Mogensen CE: Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 1987; 31:673-689.
25. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310:356-360.
26. Parving HH, Jensen H, Mogensen CE, Ervin PE: Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; i:1190-1192.
27. Redon J, Pascual JM, Miralles A, Sanz C, Gutierrez M, Ros MJ, et al.: Microalbuminuria in essential hypertension [in Spanish]. Med Clin (Barc) 1991; 96:525-529.
28. Bianchi S, Bigazzi R, Valtriani C, Chiaponni I, Sgherri G, Baldari G, et al.: Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension 1994; 23 (part 1):681-687.
29. Redon J, Miralles A, Pascual JM, Baldo E, Garcia-Robles R, Carmena R: Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. J Hypertens 1997; 15:79-86.
30. Cerasola G, Cottone S, D'Ignoto G, Grasso L, Mangano MT, Carapelle E, et al.: Microalbuminuria as a predictor of cardiovascular damage in essential hypertension. J Hypertens 1989; 7 (suppl 6):S332-S333.
31. Giaconi S, Levanti C, Fommei E, Innocenti F, Seghieri G, Palla G, et al.: Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild essential hypertension. Am J Hypertens 1989; 2:259-261.
32. Redon J, Gomez-Sanchez MA, Baldo E, Casal MC, Fernandez ML, Miralles A, et al.: Microalbuminuria correlates with left ventricular hypertrophy in male hypertensive patients. J Hypertens 1991; 9 (suppl 6): S148-S149.
33. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G: Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens 1995; 9:827-833.
34. Del Sette A, Zagami P, Angeli S, Finocchi C, Gandolfo C, Pontremoli R: Carotid diameter, wall thickness, and parietal stress in essential hypertension [abstract]. Stroke 1995; 26:2373.
35. Sievert-Delle A, Ljungman S, Hartford M, Wikstrand J: Effect of 14 years of antihypertensive treatment on renal function and urinary alumin excretion in primary hypertension. Am J Hypertens 1996; 9:841-849.
36. Peterson JC, Adler S, Burkart JM, Green T, Hebert LA, Hunsicker LG, et al.: Arterial pressure control, proteinuria and the progression of renal disease. The Modifications of Diet in Renal Disease Study. Ann Intern Med 1995; 123:754-762.
37. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levry AS, Milas NC, et al., for the Modification of Diet in renal Disease Study Group. Hypertension 1997; 29:641-650.
38. Omata K, Kanazawa M, Sato T, Abe F, Saito T, Abe K: Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Kidney Int 1996; 55 (suppl):S57-S62
39. Redon J: Ambulatory blood pressure and the kidney. Blood Pressure Monitoring 1998; (in press)
40. Lurbe E, Redon J, Pascual JM, Tacons J, Alvarez V, Batlle DC: Altered blood pressure during sleep in normotensive subjects with type 1 diabetes. Hypertension 1993; 21:227-235.
41. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155:1073-1080.
42. Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE: Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10:1963-1974.
43. Giatras I, Lau J, Levey AS, for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group: Effect of angiotensin-converting-enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Ann Intern Med 1997; 127:337-345.
44. Hollemberg NK: ACE inhibitors, AT1receptor blockers, and the kidney. Nephrol Dial Transplant 1997; 12:381-383.
45. Navis J, de Zeeuw D, de Jong PE: ACE-inhibitors: panacea for progressive renal disease? Lancet 1997; 349:1852-1853.
46. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Montolese M, et al. and the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insuficiency Study Group. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334:939-945.
47. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non diabetic nephropathy. Lancet 1997; 349:1857-1863
48. Modification of Diet in Renal Disease Study Group, Hebert L, Kusek JW, Greene T, Agodoa L, Jones CA, Levey AS, et al.: Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension 1997; 30 (part 1):428-435.
49. McLaughlin KJ, Harden PN, Ueda S, Boulton-Jones JM, Connell JMC, Jardine AG: The role of genetic polymorphism of angiotensin-converting-enzyme in the progression of renal diseases. Hypertension 1996; 28:912-915.
50. van Essen GG, Rensma PL, de Zeew D, Sluiter WJ, Scheffer H, Apperloo AJ, de Jong PE: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996; 347:94-95.
51. Cottone S, Controno A, D'Ignoto G, Cerasola G: Prevalence of microalbuminuria in essential hypertension [abstract]. Am J Hypertens 1993; 6:30A.
52. Ljungman S: Microalbuminuria in essential hypertension. Am J Hypertens 1990; 3:956-960.
53. Redon J, Lozano JV, Liao Y, Miralles A, Baldo E, Cooper RS: Factors related to the presence of microalbuminuria in essential hypertension. Am J Hypertens 1994; 7:801-807.
54. Redon J, Miralles A, Liao Y, Lozano JV, Pascual JM, Cooper RS: Circadian variability and microalbuminuria in essential hypertension. J Hypertens 1994; 12:947-954.
55. Palatini P, Graniero GR, Mormino P, Mattaret M, Sanzuol F, Cignacco GB, et al.: Prevalence and clinical correlates of microalbuminuria in stage I hypertension. Results from the hypertension and ambulatory recording Venetia study (HARVEST Study). Am J Hypertens 1996; 9:334-341.
56. Agewall S, Fagerberg B, Attvall S, Ljungman S, Urbanavicius V, Tengborn L, Wikstrand J, on behalf of the Risk Factor Intervention Study Group: Microalbuminuria, insulin sensitivity and haemostatic factors in non-diabetic treated hypertensive men. J Intern Med 1995; 237: 195-203.
57. Bianchi S, Bigazzi R, Qiñones A, Muscelli E, Baldari G, Pecori N, et al.: Insulin resistance in microalbuminuric hypertension. Sites and mechanisms. Hypertension 1995; 26:789-795.
58. Falkner B, Kushner H, Levison S, Canessa M: Albuminuria in association with insulin and sodium-lithium countertransport in young African Americans with borderline hypertension. Hypertension 1995; 25:1315-1321.
59. Campese VM: Salt sensitivity in hypertension: renal and cardiovascular implications. Hypertension 1994; 23:531-550.
60. Nesovic M, Stojanovic M, Nesovic MM, Ciric J, Zarkovic M: Microalbuminuria is associated with salt sensitivity in hypertensive patients. J Hum Hypertens 1996; 10:573-576.
61. Pontremoli R, Bezante GP, Sofia A: Deletion polymorphism of the angiotensin I converting enzyme gene is a risk factor for target organ damage in essential hypertension [abstract]. J Am Soc Nephrol 1995; 3:647.
62. Redon J, Chavez J, Pascual JM, Miralles A, Martin J, Armengod ME: ACE polymorphisms influences microalbuminuria in essential hypertension [abstract]. Am J Hypertens 1998; 194a.
63. Sommers SC, Melamed J: Renal pathology of essential hypertension. Am J Hypertens 1990; 3:583-587.
64. Christensen CK, Krusell LR: Acute and long-term effect of antihypertensive treatment on exercise induced microalbuminuria in essential hypertension. J Clin Hypertens 1987; 3:704-712.
65. Redon J, Pascual JM, Liao Y, Miralles A, Lozano JV, Cooper R: Occurrence of microalbuminuria during treatment in essential hypertension [abstract]. J Hypertens 1997; 15 (suppl 4):54.
66. Bianchi S, Bigazzi R, Baldari G, Campese VM: Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs. Am J Med 1992; 93:525-528.
67. Schmieder RE, Ruddel H, Schlebusch H, Rockstroh J, Schachinger H, Schulte W: Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy. Am J Hypertens 1992; 5:318-321.
68. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM: Long term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hypertension. Am J Hypertens 1993; 6:108-113,
69. Ribstein J, Du Cailar G, Brouard R, Mimran A: Comparative renal and cardiac effects of tertatolol and enalapril in essential hypertension. Cardiology. 1993; 83 (suppl 1):57-63.
70. Erley CM, Haefele U, Heyne N, Braun N, Risler T: Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 1993; 21 (part 1):810-815.
71. Ranieri G, Andriani A, Lamontanara G, De Cesaris R: Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension. Clin Pharmacol Ther 1994; 56:323-330.
72. Alli C, Lombardo M, Zanni D, Agrati MA, Cassani M, Granata S: Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. Am J Hypertens 1996; 9:1068-1076.
73. Schmieder RE, Langenfeld MR, Gatzka CD, Weidinger G, Schobel HP: Impact of alpha versus beta blockers on hypertensive target organ damage: results of a double blind, randomized, controlled clinical trial. Am J Hypertens 1997; 10 (part 1):985-991.
74. DeQuattro V, Lee DP: Equivalent reduction of proteinuria in hypertensives by either nifedipine GITS or enalapril: disparate effects on neurohormones and ambulatory blood pressure and the influence of salt. Cardiology 1997; 88 (suppl 3):38-42.
75. Persson B, Andersson OK, Wysocki M, Hedner T, Karlberg B: Calcium antagonism in essential hypertension: effect on renal haemodynamics and microalbuminuria. J Intern Med 1992; 231:247-252.
76. Larrochell P, for the Multicenter Study Group: Effect of quinapril on the albumin excretion rate in patients with mild to moderate essential hypertension. Am J Hypertens 1996; 9:551-559.
77. Fauvel JP, Velon S, Berra N, Pozet N, Madonna O, Zech P, Laville M: Effects of losartan on renal function in patients with essential hypertension. J Cardiovasc Pharmacol 1996; 28:259-263.
78. Nielsen S, Dollerup J, Nielsen B, Jensen HA, Mogensen CE: Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12 (suppl 2): 19-23.
79. Biesenbach G, Zazgornik J: High prevalence of hypertensive retinopathy and coronary heart disease in hypertensive patients with persistent microalbuminuria under short intensive antihypertensive therapy. Clin Nephrol 1994; 41:211-218.